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Edited by Felix WielandAbstract Coronins constitute an evolutionary conserved family
of WD-repeat actin-binding proteins. Their primary function is
thought to be regulating the actin cytoskeleton. Apart from that,
several coronins were indirectly shown to participate in vesicular
transport, establishment of cell polarity and cytokinesis. Here,
we report a novel mammalian protein, coronin 7 (crn7), which is
signiﬁcantly diﬀerent from other mammalian coronins in its
domain architecture. Crn7 possesses two stretches of WD
repeats in contrast to the other coronins only having one. The
protein is expressed throughout the mouse embryogenesis and is
strongly upregulated in brain and developing structures of the
immune system in the course of development. In adult animals,
both crn7 mRNA and protein are abundantly present in most
organs, with signiﬁcantly higher amounts in brain, kidney,
thymus and spleen and lower amounts in muscle. At the
subcellular level, the bulk of the protein appears to be present
in the cytosol and in large cytosolic complexes. However, a
signiﬁcant portion of the protein is detected on vesicle-like
cytoplasmic structures as well as on the cis-Golgi. In the Golgi
region, crn7 staining appears broader than that of the cis-Golgi
markers Erd2p and b-COP, still, the trans-Golgi network
appears predominantly crn7-negative. Importantly, the mem-
brane-associated form of crn7 protein is phosphorylated on
tyrosine residues, whereas the cytosolic form is not. Crn7 is the
ﬁrst coronin protein proven to localize to the Golgi membrane.
We conclude that it plays a role in the organization of
intracellular membrane compartments and vesicular traﬃcking
rather than in remodeling the cytoskeleton.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Coronins are a family of evolutionary conserved actin-
binding proteins found in a variety of organisms from Dicty-
ostelium to man. A common structural feature of the approx.
55 kDa coronin proteins is the presence of a conserved central
stretch of WD-40 domain repeats that are proposed to form a* Corresponding author. Fax: +49-221-478-6979.
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doi:10.1016/j.febslet.2004.07.066propeller-like structure [1] and a C-terminal coiled coil region.
The ﬁrst family member was characterized in Dictyostelium
and was shown to mediate actin cytoskeleton remodeling and
phagocytosis [2–4]. In addition to this role, the other members
have been shown to function in vesicular traﬃcking, cell di-
vision and establishment of cell polarity, although none of
these functions is completely abolished in coronin-mutant cells
(reviewed in [1]). The coiled coil regions of coronin proteins
participate in their homophilic di- and oligomerization [5,6],
whereas the WD-repeats are implied in actin binding [7,8]. In
the yeast, the coronin orthologue crn1p associates with the
Arp2/3 complex and inhibits actin nucleation in vitro, the in-
hibitory function being mapped to the coiled coil region [9].
The yeast coronin has also been shown to interact with the
microtubule cytoskeleton in an actin-dependent manner [7,10].
In mammals, most coronin-related genes are expressed in a
tissue-speciﬁc manner, only coronins 2 and 3 being ubiquitous.
Isoforms 4 and 5 are expressed in the brain, coronin 2SE in
epithelial tissues and coronin 1 in the hematopoietic lineage
and in the lung (reviewed in [1]). Not much data are available
on the functions of mammalian coronins. It was shown that
the isoform 1 (p57crn1) is localized to phagosomes and is re-
leased upon PKC-dependent phosphorylation [11]. GST-fused
recombinant coronin 1 binds actin in vitro [12]. Surprisingly,
actin binding was later conferred not only to the WD repeats,
but also to the short N-terminal region of the protein [8].
Two recently discovered Drosophila and C. elegans pro-
teins seem to constitute a novel subfamily of coronins. The
worm POD-1 and ﬂy Dpod-1 are both approximately twice
as long as conventional coronins (predicted molecular weight
of 115 and 119 kDa, respectively) and possess two stretches
of WD repeats each, but no coiled coil region. As both N-
and C-termini of POD-1 proteins possess a signiﬁcant degree
of homology to the conventional coronins, it might be
presumed that the corresponding genes have arisen due to
gene duplication. C. elegans POD-1 has been shown to
participate in polar granule traﬃcking and thus in polari-
zation of the early embryo [13]. POD-1 mutant embryos also
accumulate abnormal membranous structures in the cyto-
plasm and show a defect in the formation of secreted ex-
tracellular structures (eggshell), resulting in an increase in
osmotic sensitivity and permeability of dyes. Dpod1, the
Drosophila homologue, plays a role in the axonal growth
cone targeting and cross-links both actin and microtubules
[14]. In addition to the WD-40 domains, the Drosophilablished by Elsevier B.V. All rights reserved.
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similar to that of the microtubule-binding protein MAP1B.
Here, we report a novel mammalian coronin similar to both
POD-1 proteins. Although being considerably shorter, it pos-
sesses the same molecular architecture as the worm POD-1 and
lacks the MAP-like domain of the Dpod-1. Using a current
nomenclature [15], we named it coronin 7 (crn7). We show that
the protein is ubiquitously distributed in most human and
mouse cells and tissues throughout development. Its subcel-
lular localization suggests a role in Golgi-related vesicular
traﬃcking events.2. Materials and methods
2.1. Molecular cloning, sequence analysis
A complete human crn7 ORF was contained in the HEPG2 cDNA
clone HEP08253 (Accession No. AK025674, obtained from the MRC
Centre, Cambridge, UK). The sequence was veriﬁed and inserted in
frame into pEGFP-C1 plasmid (Clontech). Plasmid DNA used for
transfection was prepared and puriﬁed using Nucleobond AX plasmid
midi or maxi kits (Macherey and Nagel). We used the GeneBee server
(Moscow State University, Russia) for phylogenetic analysis of the
coronin family members, and ClustalW (EBI, UK) and BLAST
(NCBI) for sequence alignments.
2.2. Generation of a monoclonal antibody
A 500 bp fragment coding for the C-terminal 160 amino acids of
human crn7 was inserted into pQE30 plasmid (Qiagen) for expression
as a 6· His-tagged polypeptide. Expression in Escherichia coli M15
[pREP4] was induced with 0.5 mM IPTG. Puriﬁcation of the His-
tagged protein by nickel nitrilotriacetate (Ni-NTA) agarose (Qiagen)
aﬃnity chromatography was performed according to the manufac-
turer’s instructions. Immunization of female Balb/c mice was done
using the Immuneasy kit (Qiagen). Antibodies were generated ac-
cording to standard protocols. The monoclonal antibody derived from
the clone K37-142-1 was used for detection of crn7 protein in all the
experiments described.
2.3. Mammalian Cell Culture
NIH 3T3 cells were grown in a Dulbecco’s modiﬁed Eagle’s medium
containing 4.5 g/L glucose (Sigma), supplemented with 10% fetal calf
serum (Biochrom), 2 mM L-glutamine (Biochrom), 1 mM sodium
pyruvate (Biochrom), 100 units/ml penicillin G, and 100 lg/ml strep-
tomycin (Invitrogen). For immunostaining, the cells were grown on 12
mm glass coverslips. For drug studies, the following substances were
added to the serum-free culture medium: latrunculin B (Sigma) at 1 lg/
ml for 30 min, brefeldin A (Fluka) at 20 lg/ml for 5 min, colchicine
(Fluka) at 5 lg/ml for 30 min, nocodazole (Sigma) at 33 lM for 30
min.
2.4. Antibodies and immunoblotting
Protein samples were separated by SDS–PAGE (10% acrylamide)
and blotted onto nitrocellulose ﬁlters. Unspeciﬁc binding of the anti-
bodies was blocked with 4% skimmed milk and 1% BSA in TBS-T (10
mM Tris–HCl, pH 8.0, 150 mM NaCl, and 0.2% Tween 20). The
following primary antibodies were used: monoclonal anti-crn7
K37-142-1, b-actin speciﬁc mAb AC74 (Sigma) at 1:10 000, rabbit
polyclonal anti-Rab5 (Transduction Laboratories) at 1:250, anti-
phosphotyrosine mAb at 1:50, rabbit anti-phosphoserine/phospho-
threonine at 1:1000. Horseradish peroxidase-conjugated secondary
antibodies against murine and rabbit IgG (Pierce) were used at 1:7500
and 1:10 000, respectively.
2.5. Immunostaining and imaging
The cells were washed brieﬂy with PBS, ﬁxed with 4% paraformal-
dehyde at room temperature, rinsed with 20 mM glycine and per-
meabilized with 0.2% saponin in PBS. Saponin was present in the
buﬀers at all later stages of staining at the concentration of 0.02%.
Unspeciﬁc binding of the antibodies was blocked with 0.045% ﬁsh
gelatin and 0.5% BSA, in PBS. The following primary antibodies were
used: anti-crn7 mAb K37-142-1 at 1:75, anti-Erd2p polyclonal anti-body [16] at 1:50, polyclonal anti-TGN38 (provided by Dr. Mark
McNiven) at 1:150, polyclonal anti-LIMP1 (provided by Dr. Yoshi-
taka Tanaka) at 1:50, and polyclonal anti-b-COP at 1:50. Secondary
goat anti-mouse antibody conjugated with Cy3 (Sigma) was used at
1:2000 and sheep anti-rabbit antibody conjugated with FITC (BioRad)
at 1:1000. Coverslips were mounted in gelvatol and analyzed using a
Leica ﬂuorescent microscope as described [6]. Digital images were
acquired using SensiControl 4.03 software (PCO Computer Optics,
Germany). Immunohistochemical analysis was performed on paraﬃn-
embedded 5-lm sections of paraformaldehyde-ﬁxed murine tissues.
The deparaﬃnized sections were treated with a 1:75 dilution of aﬃnity
puriﬁed anti-crn7 antibody overnight at 4 C and a 1:500 dilution of
Alexa 488-conjugated anti-IgG1 secondary antibody (Molecular
Probes) for 2 h at room temperature. Sections were counterstained
with DAPI and visualized by ﬂuorescence microscopy.
2.6. Subcellular fractionation and two-dimensional gel electrophoresis
Subcellular fractionation experiments were performed as described
[6], except for cell homogenization which was performed by passing the
cells through a 21G 11
2
needle for 15 times. For phosphorylation assays,
all the steps were performed in the presence of 1 mM sodium ortho-
vanadate and 25 nM okadaic acid (BioChemika). Separation of
membrane organelles on discontinuous sucrose gradients and two-
dimensional gel electrophoresis were performed as described [6].3. Results
3.1. Crn7 is a mammalian POD-1 protein
We have cloned a complete cDNA for human crn7 by re-
verse-transcriptase PCR using information from the EST da-
tabase. The obtained sequence contains a single open reading
frame encoding a 924-amino acid protein (Fig. 1) with a pre-
dicted molecular weight of 100.5 kDa and a predicted iso-
electric point of 5.6. The predicted protein sequence contains
two coronin domains, as the related C. elegans POD-1 and
dPOD-1 from Drosophila do. A structural peculiarity of crn7 is
the presence of a 47-amino acid long proline, serine and
threonine-enriched stretch preceding the second group of WD
repeats designated a PST motif (Fig. 1). Crn7 protein is 46%
and 47% homologous and 30% and 29% identical to Dpod-1
and POD-1, respectively as predicted by NCBI BLAST server
using BLOSUM62 matrix. Using the information available
from the Dictyostelium discoideum genome project, we also
identiﬁed a closely related predicted protein in Dictyostelium.
DdPOD-1 is a 962 amino acid protein 50% homologous and
29% identical to crn7 and possessing the same molecular ar-
chitecture, including a PST motif. Phylogenetic analysis using
cluster algorithm clearly positions crn7, ddPOD-1 and both
previously described POD-1 proteins in a group distinct from
other coronins (Fig. 2).
3.2. Tissue distribution and developmental dynamics of crn7
We have studied the localization of crn7 protein and mRNA
in cells and tissues using our monoclonal antibody mAb K37-
142-1 generated against a C-terminal polypeptide for Western
blot and a full-length cDNA for Northern blot analysis. As
indicated by Northern blots, the approximately 4 kb crn7
mRNA is present in the mouse embryonic tissues as early as at
the day 5 p.c., and is signiﬁcantly elevated to the day 15 (data
not shown). Crn7 mRNA is expressed in the majority of mouse
tissues, except for the lung, with a strong increase in brain,
thymus and kidney (Fig. 3A). This pattern roughly corre-
sponds to that of crn7 protein recognized by mAb K37-142-1
at approx. 100 kDa. The protein levels are comparatively low
in both skeletal and heart muscle (Fig. 3B). The discrepancy
Fig. 1. Sequence alignment of human crn7 protein with POD-1 proteins from Drosophila and C. elegans. The coronin domains are highlighted in
gray, the serine-, proline-, threonine-enriched sequence of crn7 is underlined.
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Fig. 2. Phylogenetic analysis of the coronin family members, including
POD-1 proteins, performed using the cluster algorithm. dmPOD-1,
Drosophila dPOD-1 protein; cePOD1, C. elegans POD-1; ddPOD-1,
predicted POD-1 protein from Dictyostelium; hsCrn1, 3, 7, human
coronins 1, 3 and 7, respectively; ddCrn, Dictyostelium coronin; scCrn,
yeast (Saccharomyces cerevisiae) coronin; ddVLDN, Dictyostelium
villidin; hsb0-COP, human b0-COP. Multiple WD-repeat proteins vil-
lidin and b0-COP are clearly forming outgroups with regard to both
coronins and POD-1 proteins. The bar corresponds to 10% of amino
acid substitution within the branch.
Fig. 3. Tissue distribution of the crn7 mRNA and protein. (A) total
RNA from selected murine tissues was hybridized with the radioac-
tively labeled crn7-speciﬁc probe. 1, brain; 2, heart; 3, liver; 4, lung; 5,
kidney; 6, testis; 7, muscle; 8, thymus. (B) tissue lysates were separated
on 10% SDS–polyacrylamide gels, blotted onto a nitrocellulose ﬁlter
and probed with monoclonal anti-crn7 antibody K37-142-1. Lane
description as in (A). Anti-b-actin monoclonal antibody was used to
conﬁrm equal loading (data not shown).
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indicate the presence of translational regulation of crn7. Using
indirect immunoﬂuorescence, we studied the developmental
expression of the protein. The strongest expression is found in
the embryonic brain, thymus, intestine, skin and in the eye. In
the brain cortex, the crn7 protein is restricted to the most
apical cell layers before embryonic day 10 (Fig. 4A and B) and
shifted to a population of more basal cells thereafter (Fig. 4CFig. 4. Immunolocalization of the crn7 protein in paraformaldehyde-ﬁxed mu
embryonic days 5, 10, 20 and 30, respectively. (E)–(G) Section through t
(H) Localization of the crn7 protein in the Purkinje cell bodies (arrows) an
respectively, at the day 16 of development. Top of the images A–G and I corr
was performed using monoclonal anti-crn7 antibody K37-142-1 (green in I–K
secondary antibody. Sections were counter-stained with DAPI (blue in I–K)and D), whereas in the hypothalamus the protein is detected in
the same set of profound big neurons throughout development
(Fig. 4E–G). In addition, the protein is found in the bodies and
dendrites of Purkinje cells in the cerebellum (Fig. 4H). In the
skin, crn7 is only present in the apical epidermis layers
(Fig. 4I). The diﬀerentiating cells in the embryonic eye are also
found to be crn7 positive (Fig. 4K). Here, crn7 is found in
developing lens ﬁbers. In adult mice, the protein is strongly
expressed in the outer plexiform layer of the retina, where the
rods are located (data not shown). Interestingly, in the intes-
tine, the protein is found not only in terminally diﬀerentiated
epithelial cells, but also in the crypt epithelium where the stem
cells are located (Fig. 4J).
3.3. Subcellular localization of crn7
Using indirect immunoﬂuorescence, we analyzed the cellular
distribution of crn7. The protein is found in vesicle-like
structures and in a Golgi-like perinuclear compartment
(Fig. 5). The crn7-positive perinuclear structure is most
prominent in NIH 3T3 ﬁbroblasts, although most otherrine embryonic tissues. (A)–(D) Sections through the brain cortex at the
he hippocampus at the embryonic days 10, 20 and 30, respectively.
d dendrites (arrowheads). (I)–(K) Embryonic skin, intestine and lens,
espond to the apical side of the corresponding organs. Immunostaining
). Primary antibodies were detected by Alexa 488-conjugated anti-IgG1
.
Fig. 5. Immunolocalization of the crn7 protein in NIH 3T3 cells. Paraformaldehyde-ﬁxed cells were stained with monoclonal anti-crn7 antibody K37-
142-1 (B, E, H) and rabbit polyclonal antibodies against either Erd2p (A), b-COP (D), or TGN38 (G). Primary antibodies were detected with goat
anti-mouse antibody conjugated with Cy3 (red) and sheep anti-rabbit antibody conjugated with FITC (green). (C), (F), (I) Merged false color images.
Insets in C, F, I correspond to the areas marked in A–C, D–F and G–I, respectively. Bar, 10 lm.
V. Rybakin et al. / FEBS Letters 573 (2004) 161–167 165studied cell types show a similar pattern of distribution (data
not shown). Crn7 protein co-localizes with cis-Golgi markers
b-COP and Erd2p in the Golgi region as shown by indirect
immunoﬂuorescence (Fig. 5). It is noteworthy that (a) in both
cases the crn7 antibody stains a broader trans-Golgi region
than do both Golgi marker antibodies (Fig. 5C and F, arrows),
and (b) the cytosolic crn7-positive vesicles are clearly distinct
from the Erd2p- or b-COP-positive ones. cis-Golgi localization
of crn7 was further conﬁrmed by immunostaining NIH 3T3
ﬁbroblasts expressing GFP-fused cis-Golgi markers p23 and
GM130 with crn7 antibody (data not shown). Importantly,
although we were able to observe a certain co-localization of
crn7 with the trans-Golgi marker TGN38, such co-localization
was restricted to the proximal Golgi region and almost absent
in the trans-most cisternae (Fig. 5I).
Upon treatment with brefeldin A, an agent leading to the
disruption of the Golgi and its fusion with the ER, the peri-
nuclear crn7-labeled structure disappears and crn7-staining
occurs in dots (Fig. 6A–C). As a control for this experiment,
we used the Erd2-speciﬁc polyclonal antibody [16] which
showed a similar staining pattern and still partially co-local-ized with crn7 after BFA treatment. Upon treatment with 5 lg/
ml colchicine for 30 min, the perinuclear crn7- and the Erd2-
positive compartment disassemble, both markers staying par-
tially co-localized (Fig. 6D–F). The same result was obtained
by using nocodazole at 33 lM for 30 min (data not shown). A
similar disassembly of the crn7-labelled structure is also ob-
served in mitotic cells (data not shown). In spite of our data
indicating the inﬂuence of microtubule-disrupting agents on
the architecture of the crn7-positive Golgi compartment and
the observation that this compartment partially co-localizes
with microtubules (data not shown), we assume that such co-
localization reﬂects the ability of the corresponding membrane
structures to bind to the microtubule network [17] rather than
indicating a direct binding of the crn7 protein to tubulin as
crn7 lacks any known MT-interacting motifs. We did not
observe any co-localization of the cytosolic crn7 structures
with actin ﬁlaments (data not shown).
The cytoplasmic crn7-labeled structures (Fig. 5) do not
correspond to the intermediates of the endocytic pathway, as
they do not co-localize with transferrin-positive compartments
after 1, 5, 10, 30 or 60 min of the internalization of FITC-
Fig. 6. Inﬂuence of brefeldin A and colchicine on cellular distribution
of crn7. (A)–(C) Cells treated with 20 lg/ml brefeldin A for 5 min. (D)–
(F) Cells treated with 5 lg/ml colchicine for 30 min. (J), (I) Anti-crn7
antibody. (B), (E) Anti-Erd2p antiserum. (C), (F) Merged false color
images (colors as in Fig. 5).
Fig. 7. (A) Diﬀerential centrifugation experiment showing the presence
of the crn7 protein in heavy membrane/cytoskeletal fraction
(10 000 · g pellet, lane 1), light membrane fraction (100 000 · g pellet,
lane 2), cytosolic protein complexes (200 000 · g pellet, lane 3) and
cytosol (200 000 · g supernatant, lane 4) of NIH 3T3 cells. (B) Two-
dimensional gel electrophoresis of the proteins present in the 10 000 · g
supernatant fraction corresponding to the lanes 2–4 in 6A (top panel),
and pellet fraction corresponding to the lane 1 in 6A (bottom panel).
After separation, the gel was blotted onto a nitrocellulose membrane
and probed with mAb K37-142-1. (C), (D) Analysis of tyrosine
phosphorylation of the crn7 protein. The protein was immunoprecip-
itated from the 10 000 · g pellet (lane 1) and supernatant (lane 2) using
mAb K37-142-1. After separation, the gel was blotted onto the ni-
trocellulose membrane and probed with anti-phosphotyrosine (C) or
anti-crn7 (D) antibody. (E), (F) Solubilization of the membrane
compartments from the 10 000 · g pellet with Triton X-100. The
10 000 · g pellet was resuspended in homogenization buﬀer [6] and
separated into two aliquots. One aliquot was treated with 0.5% Triton
X-100 for 30 min at 4 C, the other one served as control. Both
aliquots were centrifuged again and the pellets and supernatants an-
alyzed by Western blot. Lane 1 shows the 10 000 · g pellet; lane 2, the
supernatant. E, control pellet; F, Triton X-100-treated pellet. Top
panels, Western blot with anti-crn7 antibody; bottom panels, with
anti-b-actin antibody.
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staining (data not shown). We assume that these structures
may be the Golgi/ER export vesicles. Another possibility is
that they represent large protein complexes constituting the
cytosolic pool of the crn7 protein.
To further conﬁrm our results concerning the subcellular
localization of crn7, we performed diﬀerential centrifugation
experiments. The protein is unequally distributed between the
cytosol and membrane fractions, the bulk of it being found in
the cytosol (Fig. 7A), where it is present in a free state
(200 000 · g supernatant) as well as in large protein complexes
(200 000 · g pellet). The membrane-associated crn7 protein
can be extracted from the 10 000 · g fraction upon treatment
with Triton X-100 (Fig. 7E and F, upper panels). As a control,
we used anti-b-actin antibody (Fig. 7E and F, lower panels),
showing that only the detergent-sensitive membrane compo-
nents have been extracted, but not cytoskeletal elements.
Separation of the post-nuclear supernatant on the discon-
tinuous sucrose gradient has revealed that the protein frac-
tionates in two sharp peaks corresponding to approx. 10–15%
and 40–50% of sucrose, thus indicating the presence of the
protein in light (vesicles) and heavy (Golgi) membrane com-
partments, respectively (data not shown).
3.4. Properties of cytosolic and membrane-associated forms of
crn7
We also analyzed the crn7 protein in membrane and cyto-
solic fractions by means of 2D gel electrophoresis. Our results
evidence that the pI values of the cytosolic form of the protein
range between 5.2 and 6.0 with a peak corresponding to the
predicted value of 5.6, whereas the membrane-associated form
has pI values ranging from 4.5 to 6.0 (Fig. 7B), inferring that
the membrane bound form is phosphorylated. Furthermore,
when we immunoprecipitated crn7 from the cytosol and
membrane fractions (10 000 · g pellet) using mAb K37-142-1
coupled to protein G-sepharose beads in the presence of
phosphatase inhibitors, the precipitated protein speciﬁcally
reacted with an anti-tyrosine antibody. No labeling was ob-
served with phosphoserine/threonine speciﬁc antibodies (data
not shown). Moreover, our results indeed conﬁrm that it is themembrane-associated, but not cytosolic form of crn7 which is
phosphorylated on tyrosine residue(s) (Fig. 7C). There are
several conserved tyrosines in the protein sequence that might
be the targets for phosphorylation. Y738 is conserved among
both crn7, POD-1, Dpod-1 and mammalian coronins 2A and
3, Y712 is conserved in crn7, and both POD-1 proteins. Sev-
eral other tyrosine residues are present in crn7 and one or
several coronins or POD-1 proteins.4. Discussion
In the present study we characterize crn7, a novel ubiquitous
mammalian protein. In contrast to the other coronin family
members, it possesses two coronin domains, each consisting of
several tandem WD repeats. Another remarkable feature of
crn7 is a short serine-, proline- and threonine-rich low com-
plexity region immediately C-terminal to the second coronin
domain.
According to our results, crn7 is present as early as at the
day 5 of mouse embryonic development in the majority of
tissues and is upregulated in brain and thymus in the course of
development. The data on tissue distribution of the protein
imply that the protein is involved in cell diﬀerentiation events,
involving the establishment of cell polarity. For example, crn7
V. Rybakin et al. / FEBS Letters 573 (2004) 161–167 167is strongly expressed in the anterior-most parts of the lens cells
in the developing eye, as well as in apical layers of the epi-
dermis, in diﬀerentiated intestinal epithelium cells and in sev-
eral subsets of brain neurons. All these cells do indeed change
their morphology as they diﬀerentiate, the changes including
polarization and development of cell extensions.
As we demonstrate here, crn7 is present in the cytosol and to
the lesser extent on vesicles and at the Golgi. Since, according
to sequence analysis, the protein lacks both transmembrane
domains and signal peptides, we assume that it is rather lo-
calized to the cytoplasmic side of the Golgi membrane than to
the luminal side or the lumen itself. Furthermore, our data
clearly evidence that the detergent-sensitive membrane-asso-
ciated pool of crn7 protein is phosphorylated on tyrosine,
while the cytosolic one is not. Thus, phosphorylation may act
as a signal controlling the membrane localization of crn7
protein. Importantly, crn7 does not bind F-actin, which is in a
stark contrast to the other coronins and POD-1 proteins.
Several conventional coronins are also localized to the in-
termediates of the intracellular membrane traﬃcking pathways
[11,18]. Taking into consideration the fact that crn7 does not
co-localize with actin in any of the cells studied, we suggest
that its WD repeats play a role diﬀerent from actin binding. In
this context it is particularly interesting that, apart from actin-
binding proteins (such as Arp2/3 complex subunits or AIP1),
two of the coatomer proteins participating in Golgi-related
vesicular traﬃcking, namely a- and b0-COP, also possess sev-
eral N-terminal WD repeats each. Furthermore, rabconnectin
3, an adaptor protein scaﬀolding both GDP/GTP exchange
protein and GTPase-activating protein for Rab3 on synaptic
vesicles, is predicted to have 12 WD domains [19]. Taken to-
gether, these data imply that crn7 and other multi-WD40 do-
main proteins may act as localized platforms for clustering
either cargo, coatomer or regulatory molecules on the intra-
cellular membranes and thus regulate the traﬃcking. Crn7
protein may function in this way by being translocated from
the cytosol to the speciﬁc domains of the Golgi membrane
upon tyrosine phosphorylation. As it was established previ-
ously, tyrosine phosphorylation does indeed act as a signal to
recruit a variety of proteins to the membranes [20,21].
Other POD-1 proteins may also participate in the intracel-
lular traﬃcking events. Indeed, the properties of the worm
protein indicate that its function is related to the membrane
transport. For instance, the eggshell defect of the POD-1
mutant worm embryos [13] implies that the protein is required
for the correct secretion. Also, mislocalization of the polar
granules and accumulation of abnormal membrane structures
in the mutant embryos strongly indicate that POD-1 is needed
for targeting the intracellular vesicles to the appropriate lo-
cations. On the other side, in Dpod1 mutant ﬂy embryos, the
axons in the developing nervous system exhibit guidance de-
fects; neuronal overexpression of Dpod1 is also suﬃcient to
disrupt the guidance. Furthermore, overexpression of the
Dpod-1 protein in S2 cells causes them to form neurite-like
actin-enriched processes [14]. Noteworthy, the Drosophila
homologue seems to be at least partially localized to the per-
inuclear actin-unrelated compartment and to cytosolic vesicle-
like structures in S2 cells, although the authors do not discuss
this ﬁnding [14]. To summarize, both ﬂy and worm proteins
clearly demonstrate cell polarity-related functions and proba-
bly execute those by regulating membrane traﬃcking. Our data
are thus in good agreement with those available for otherunconventional coronins. It is however noteworthy that both
POD-1 and Dpod-1 bind to F-actin, whereas crn7 does not.
Two arising possibilities are that either crn7 interacts with the
cytoskeletal elements via adaptor proteins, or it functions in
cytoskeleton-independent manner.
To summarize, we propose a role for crn7 in the develop-
mental events involving the ER-to-Golgi traﬃcking and re-
sulting in establishment of polarity in cells and embryos.
Further studies will be required to unravel the function of crn7
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